Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come
Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy, Ozempic, and Rybelsus), owned by Novo Nordisk; and tirzepatide (Zepbound, Mounjaro), owned by Eli Lilly. All five of those drug brands, with the exception of Rybelsus, are administered by injection, whereas Rybelsus is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and Wegovy was also approved by the FDA in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more
塞马卢肽正在被研究用于心脏病、阿尔茨海默病、肝病等多种应用
GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come
预计GLP-1药物将在未来几年产生数千亿的营业收入
KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following strategic update.
基洛纳，BC / ACCESSWIRE / 2024年11月26日 / Lexaria Bioscience corp. (纳斯达克：LEXX)(纳斯达克：LEXXW)（"公司"或"Lexaria"），作为全球药物递送平台的创新者，提供以下战略更新。
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy, Ozempic, and Rybelsus), owned by Novo Nordisk; and tirzepatide (Zepbound, Mounjaro), owned by Eli Lilly. All five of those drug brands, with the exception of Rybelsus, are administered by injection, whereas Rybelsus is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and Wegovy was also approved by the FDA in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.
今天的GLP-1药物市场主要由塞马卢肽（Wegovy、Ozempic和Rybelsus）构成，属于诺和诺德；以及提泽帕肽（Zepbound、Mounjaro），属于礼来。除了Rybelsus之外的那五种药物品牌，均通过注射给药，而Rybelsus是目前FDA批准的唯一口服药片。虽然这两种药物最初获得FDA批准用于糖尿病管理，但不久之后就获得了减重批准，Wegovy还在2024年3月获得FDA批准，以降低心血管死亡、心脏病发作和中风的风险。
Acceptance and use of these two drugs by the public has resulted in unprecedented demand, with estimates of 2024 revenue between them of ~$30 billion, compared to just $300 million in 2018, an increase of 100x or 10,000%.
公众接受和使用这两种药物导致了前所未有的需求，预计2024年的营业收入将在30亿美元左右，而2018年仅为3000万美元，增长了100倍或10,000%。
译文内容由第三方软件翻译。
